Germany on Monday suspended the use of the Astra Zeneca’s COVID-19 vaccine, over new reports of dangerous blood clots in connection with the shot.

The Health Ministry said the decision was taken as a "precaution" and on the advice of Germany's national vaccine regulator, the Paul Ehrlich Institute, which called for further investigation of the cases.

"After new reports of thromboses of the cerebral veins in connection with the vaccination in Germany and Europe, the PEI considers further investigations to be necessary," said the German health ministry. 
 
AstraZeneca Update: EU faces vaccine shortage, supplies to be blamed

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/astrazeneca-update-eu-faces-vaccine-shortage-supplies-to-be-blamed-370677/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

"The European Medicines Agency EMA will decide whether and how the new findings will affect the approval of the vaccine," it added.

Denmark, Iceland and Norway have already stopped administering the shot while Italy has banned the use of a batch of AstraZeneca doses as a precaution after an unconfirmed number of people developed blood clots.

Meanwhile, the World Health Organization appealed to countries not to pause vaccination campaigns after two more European nations and one in Asia joined handfuls which have suspended the use of AstraZeneca's Covid-19 vaccine over safety fears.

The WHO said its advisory panel was reviewing reports related to the shot and would release its findings as soon as possible. But it said it was unlikely to change its recommendations, issued last month, for widespread use, including in countries where the South African variant of the virus may reduce its efficacy.

AstraZeneca's shot was among the first and cheapest to be developed and launched at volume since the coronavirus was first identified in central China at the end of 2019 and is set to be the mainstay of vaccination programmes in much of the developing world. The virus has killed more than 2.7 million people.

(With inputs from agencies)

Germany on Monday suspended the use of the Astra Zeneca’s COVID-19 vaccine, over new reports of dangerous blood clots in connection with the shot. The Health Ministry said the decision was taken as a "precaution" and on the advice of Germany's national vaccine regulator, the Paul Ehrlich Institute, which called for further investigation of the cases.

Germany on Monday suspended the use of the Astra Zeneca’s COVID-19 vaccine, over new reports of dangerous blood clots in connection with the shot. The Health Ministry said the decision was taken as a "precaution" and on the advice of Germany's national vaccine regulator, the Paul Ehrlich Institute, which called for further investigation of the cases. "After new reports of thromboses of the cerebral veins in connection with the vaccination in Germany and Europe, the PEI considers further investigations to be necessary," said the German health ministry. AstraZeneca Update: EU faces vaccine shortage, supplies to be blamed "The European Medicines Agency EMA will decide whether and how the new findings will affect the approval of the vaccine," it added. Denmark, Iceland and Norway have already stopped administering the shot while Italy has banned the use of a batch of AstraZeneca doses as a precaution after an unconfirmed number of people developed blood clots. Meanwhile, the World Health Organization appealed to countries not to pause vaccination campaigns after two more European nations and one in Asia joined handfuls which have suspended the use of AstraZeneca's Covid-19 vaccine over safety fears. The WHO said its advisory panel was reviewing reports related to the shot and would release its findings as soon as possible. But it said it was unlikely to change its recommendations, issued last month, for widespread use, including in countries where the South African variant of the virus may reduce its efficacy. AstraZeneca's shot was among the first and cheapest to be developed and launched at volume since the coronavirus was first identified in central China at the end of 2019 and is set to be the mainstay of vaccination programmes in much of the developing world. The virus has killed more than 2.7 million people. (With inputs from agencies)

Germany suspends AstraZeneca jabs over reported clot risks: Health Ministry

European Union vaccination drive stumbles as the production supply becomes the main reason for AstraZeneca shortage. Several countries have suspended the AstraZeneca vaccine over blood clot fears.

AstraZeneca Update: EU faces vaccine shortage, supplies to be blamed

AstraZeneca said that a review of safety data of people vaccinated with its COVID-19 vaccine has shown no evidence of an increased risk of blood clots.

AstraZeneca finds no evidence of blood clot risk from vaccine

The British-Swedish company AstraZeneca said that a safety review of people inoculated with its COVID-19 vaccine has shown no evidence of increased risk of blood clots.

AstraZeneca: No proof of risk of blood clots found

Piedmont region in northern region said on Sunday that it was stopping the use of a batch of AstrazZeneca COVID vaccine. This step has been taken after a teacher died following receiving vaccine on Saturday.

The region, around the northern city of Turin, had initially suspended all AstraZeneca vaccines in order to identify and isolate the batch from which the jab administered to the teacher, from the town of Biella, came.

The regional government said that the decision to suspend use was a precautionary measure. Piedmont is awaiting the results of checks which will verify whether there is a connection between the death and the vaccination

The statement did not specify what batch it had banned nor did it say how the teacher died. Italian newspapers reported it was batch ABV5811. A source close to the regional government confirmed it was batch ABV5811.

The regional government's statement said that the Piedmont region was also awaiting decisions from Italy's medicine's agency Aifa and a regional health commission on the issue.

"It is an act of extreme prudence, while we verify whether there is a connection. There have been no critical issues with the administration of vaccines to date," Luigi Genesio Icardi, head of regional health services, said in the statement.

Italy's medicine authority Aifa on Thursday banned the use of doses of the AstraZeneca vaccine belonging to the ABV2856 batch. Sources told Reuters the decision had been taken after the deaths of two men in Sicily.

Aifa had said that the ban was precautionary, adding that no link had been established between the vaccine and subsequent "serious adverse events".

(With AFP inputs)

Piedmont region in northern region said on Sunday that it was stopping the use of a batch of AstrazZeneca COVID vaccine. This step has been taken after a teacher died following receiving vaccine on Saturday.

Piedmont region in northern region said on Sunday that it was stopping the use of a batch of AstrazZeneca COVID vaccine. This step has been taken after a teacher died following receiving vaccine on Saturday. The region, around the northern city of Turin, had initially suspended all AstraZeneca vaccines in order to identify and isolate the batch from which the jab administered to the teacher, from the town of Biella, came. The regional government said that the decision to suspend use was a precautionary measure. Piedmont is awaiting the results of checks which will verify whether there is a connection between the death and the vaccination The statement did not specify what batch it had banned nor did it say how the teacher died. Italian newspapers reported it was batch ABV5811. A source close to the regional government confirmed it was batch ABV5811. The regional government's statement said that the Piedmont region was also awaiting decisions from Italy's medicine's agency Aifa and a regional health commission on the issue. "It is an act of extreme prudence, while we verify whether there is a connection. There have been no critical issues with the administration of vaccines to date," Luigi Genesio Icardi, head of regional health services, said in the statement. Italy's medicine authority Aifa on Thursday banned the use of doses of the AstraZeneca vaccine belonging to the ABV2856 batch. Sources told Reuters the decision had been taken after the deaths of two men in Sicily. Aifa had said that the ban was precautionary, adding that no link had been established between the vaccine and subsequent "serious adverse events". (With AFP inputs)

Piedmont region in Italy stops use of AstraZeneca vaccine batch

AstraZeneca COVID vaccine: These countries have suspended its use so far

After several European countries decided to impose a temporary ban on the usage of AstraZeneca's <a href="https://www.wionews.com/topics/coronavirus-vaccine">coronavirus vaccine</a>, Ireland has also decided to suspend the use of this vaccine.

"The administration of COVID-19 Vaccine AstraZeneca is temporarily deferred from this morning, Sunday 14th March," a health ministry spokesperson told the news agency AFP.

Also read |&nbsp;<a href="https://www.wionews.com/world/norway-probes-blood-clot-cases-after-astrazeneca-vaccine-suspension-370309">Norway probes blood clot cases after AstraZeneca vaccine suspension</a>

This decision has been taken after there were several reported cases of blood clots being formed in people who took a shot of AstraZeneca's coronavirus vaccine.

Earlier, Ireland's National Immunisation Advisory Committee (NUAC) had recommended suspending the rollout of AstraZeneca as a "precautionary principal" after "a report from the Norwegian Medicines Agency of four new reports of serious blood clotting events in adults after vaccination".

While it hasn't been concluded yet if there is any link between the AstraZeneca coronavirus vaccine and the blood clot cases, Ireland claims the decision has been taken "pending receipt of further information," Ireland's deputy chief medical officer Ronan Glynn said.

<a href="https://www.wionews.com/videos/european-union-faces-shortfall-of-astrazeneca-vaccine-370391">Watch |</a>

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/european-union-faces-shortfall-of-astrazeneca-vaccine-370391/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

As of now, nearly 570,000 doses of the AstraZeneca vaccine have been administered in Ireland, as per government data.

Meanwhile, AstraZeneca has denied these claims saying, "An analysis of our safety data that covers reported cases from more than 17 million doses of vaccine administered has shown no evidence of an increased risk" in blood clot conditions.

"In fact, the reported numbers of these types of events for COVID-19 Vaccine AstraZeneca are lower than the number that would have occurred naturally in the unvaccinated population," the statement read.

Ireland's announcement came a few hours after Norway reported three more cases of blood clots or brain haemorrhages in younger people who received the AstraZeneca Covid-19 jab, but said they could not yet say they were vaccine-related.

After several European countries decided to impose a temporary ban on the usage of AstraZeneca's coronavirus vaccine, Ireland has also decided to suspend the use of this vaccine.

After several European countries decided to impose a temporary ban on the usage of AstraZeneca's coronavirus vaccine, Ireland has also decided to suspend the use of this vaccine. "The administration of COVID-19 Vaccine AstraZeneca is temporarily deferred from this morning, Sunday 14th March," a health ministry spokesperson told the news agency AFP. Also read | Norway probes blood clot cases after AstraZeneca vaccine suspension This decision has been taken after there were several reported cases of blood clots being formed in people who took a shot of AstraZeneca's coronavirus vaccine. Earlier, Ireland's National Immunisation Advisory Committee (NUAC) had recommended suspending the rollout of AstraZeneca as a "precautionary principal" after "a report from the Norwegian Medicines Agency of four new reports of serious blood clotting events in adults after vaccination". While it hasn't been concluded yet if there is any link between the AstraZeneca coronavirus vaccine and the blood clot cases, Ireland claims the decision has been taken "pending receipt of further information," Ireland's deputy chief medical officer Ronan Glynn said. Watch | As of now, nearly 570,000 doses of the AstraZeneca vaccine have been administered in Ireland, as per government data. Meanwhile, AstraZeneca has denied these claims saying, "An analysis of our safety data that covers reported cases from more than 17 million doses of vaccine administered has shown no evidence of an increased risk" in blood clot conditions. "In fact, the reported numbers of these types of events for COVID-19 Vaccine AstraZeneca are lower than the number that would have occurred naturally in the unvaccinated population," the statement read. Ireland's announcement came a few hours after Norway reported three more cases of blood clots or brain haemorrhages in younger people who received the AstraZeneca Covid-19 jab, but said they could not yet say they were vaccine-related.

Ireland suspends use of AstraZeneca coronavirus vaccine

The European Union is facing a further shortfall in its Coronavirus inoculation program. This after the pharmaceutical giant AstraZeneca said that production problems and experts restrictions would reduce plan deliveries of its vaccine. Several countries have suspended the AstraZeneca vaccine over blood clot fears. ‌

European union faces shortfall of AstraZeneca vaccine

European Union is facing fresh shortfall of coronavirus vaccines after Anglo/Swedish pharmaceutical giant AstraZeneca said production problems and export restrictions would reduce vaccine delivery. Several countries have suspended use of AstraZeneca vaccines over blood clot fears. AstraZeneca's image has taken a hit even after World Health Organisation (WHO) said that there was no reason to stop using it.

The company had previously warned it was facing shortfalls from its European supply chain due to "lower-than-expected output from the production process" and was hoping to compensate in part by sourcing vaccines from its global network.

"Unfortunately, export restrictions will reduce deliveries in the first quarter, and are likely to affect deliveries in the second quarter," it confirmed in a statement sent to AFP on Saturday.

'Unacceptable'

AstraZeneca started delivering vaccines to European Union in February. It aims to deliver 100 million doses in first half of 2021.

AstraZeneca had initially agreed to supply three times as many doses in the first quarter, and 180 million doses in second quarter alone.

The EU on Saturday sidestepped the issue of the number of AstraZeneca doses it was expecting. "We are aware that the company is experiencing supply issues and that discussions are on-going," it said.

Germany has already reported adverse effects due to the delay, the state of Thuringia cancelling appointments and suspending a pilot project for general practitioners to administer the vaccine.

Thuringia had been due to receive 31,200 doses next week, but the number has been reduced to 9,600.

The state's health minister, Heike Werner, called the delay "absolutely unacceptable".&nbsp;

French Prime Minister Jean Castex said his government still expected to exceed a target of 10 million vaccinated by April 15, though he deplored that some labs were not respecting delivery deadlines.

Castex defended the use of the AstraZeneca jab despite precautions taken by other nations.

"I would not allow myself to send poison to my fellow citizens," he said during a visit to a vaccination centre.

(With AFP inputs)

European Union is facing fresh shortfall of coronavirus vaccines after Anglo/Swedish pharmaceutical giant AstraZeneca said production problems and export restrictions would reduce vaccine delivery.

European Union is facing fresh shortfall of coronavirus vaccines after Anglo/Swedish pharmaceutical giant AstraZeneca said production problems and export restrictions would reduce vaccine delivery. Several countries have suspended use of AstraZeneca vaccines over blood clot fears. AstraZeneca's image has taken a hit even after World Health Organisation (WHO) said that there was no reason to stop using it. The company had previously warned it was facing shortfalls from its European supply chain due to "lower-than-expected output from the production process" and was hoping to compensate in part by sourcing vaccines from its global network. "Unfortunately, export restrictions will reduce deliveries in the first quarter, and are likely to affect deliveries in the second quarter," it confirmed in a statement sent to AFP on Saturday. 'Unacceptable' AstraZeneca started delivering vaccines to European Union in February. It aims to deliver 100 million doses in first half of 2021. AstraZeneca had initially agreed to supply three times as many doses in the first quarter, and 180 million doses in second quarter alone. The EU on Saturday sidestepped the issue of the number of AstraZeneca doses it was expecting. "We are aware that the company is experiencing supply issues and that discussions are on-going," it said. Germany has already reported adverse effects due to the delay, the state of Thuringia cancelling appointments and suspending a pilot project for general practitioners to administer the vaccine. Thuringia had been due to receive 31,200 doses next week, but the number has been reduced to 9,600. The state's health minister, Heike Werner, called the delay "absolutely unacceptable". French Prime Minister Jean Castex said his government still expected to exceed a target of 10 million vaccinated by April 15, though he deplored that some labs were not respecting delivery deadlines. Castex defended the use of the AstraZeneca jab despite precautions taken by other nations. "I would not allow myself to send poison to my fellow citizens," he said during a visit to a vaccination centre. (With AFP inputs)

EU: Fresh shortfall of AstraZeneca COVID vaccine supplies

Thailand has delayed its roll-out of the AstraZeneca Covid vaccine, a health official said Friday, after several European nations suspended their programmes over blood clot fears.

The kingdom was scheduled to start the Oxford/AstraZeneca vaccine roll-out on Friday, with Prime Minister Prayut Chan-O-Cha expected to get the first jab.

"Vaccine injection for Thais must be safe, we do not have to be in a hurry," said Piyasakol Sakolsatayadorn, an advisor for the country's Covid-19 vaccine committee, in a press conference.

"Though the quality of AstraZeneca is good, some countries have asked for a delay. We will delay (as well)."&nbsp;

The move comes after Denmark, Norway and Iceland suspended the use of the Oxford/AstraZeneca jab the day before.&nbsp;

Austria on Sunday stopped using doses from one batch after a 49-year-old nurse died of "severe blood coagulation problems" days after receiving an anti-Covid shot.

However, there is still no established link between the vaccine and side effects of blood clots, and Denmark stressed that its move was merely precautionary as they examine the risks more closely.&nbsp;

"We are waiting for Denmark and Austria to make a conclusion," said virologist Yong Poovarawan. &nbsp;

"We are delaying to let others prove (the side effects) of whether or not it is because of the vaccine or if it is only on that specific batch," he said, adding that the batch Thailand has received was manufactured in a factory in Asia.&nbsp;

Thailand appears to have escaped the brunt of the coronavirus, registering 26,000 cases and 85 deaths.&nbsp;

It had already rolled out its vaccination campaign last month with the Chinese-made Sinovac vaccine, and health workers were the first to receive the injections on February 28.

Thailand has delayed its roll-out of the AstraZeneca Covid vaccine, a health official said Friday, after several European nations suspended their programmes over blood clot fears.

Thailand has delayed its roll-out of the AstraZeneca Covid vaccine, a health official said Friday, after several European nations suspended their programmes over blood clot fears. The kingdom was scheduled to start the Oxford/AstraZeneca vaccine roll-out on Friday, with Prime Minister Prayut Chan-O-Cha expected to get the first jab. "Vaccine injection for Thais must be safe, we do not have to be in a hurry," said Piyasakol Sakolsatayadorn, an advisor for the country's Covid-19 vaccine committee, in a press conference. "Though the quality of AstraZeneca is good, some countries have asked for a delay. We will delay (as well)." The move comes after Denmark, Norway and Iceland suspended the use of the Oxford/AstraZeneca jab the day before. Austria on Sunday stopped using doses from one batch after a 49-year-old nurse died of "severe blood coagulation problems" days after receiving an anti-Covid shot. However, there is still no established link between the vaccine and side effects of blood clots, and Denmark stressed that its move was merely precautionary as they examine the risks more closely. "We are waiting for Denmark and Austria to make a conclusion," said virologist Yong Poovarawan. "We are delaying to let others prove (the side effects) of whether or not it is because of the vaccine or if it is only on that specific batch," he said, adding that the batch Thailand has received was manufactured in a factory in Asia. Thailand appears to have escaped the brunt of the coronavirus, registering 26,000 cases and 85 deaths. It had already rolled out its vaccination campaign last month with the Chinese-made Sinovac vaccine, and health workers were the first to receive the injections on February 28.

Thailand delays AstraZeneca vaccine rollout

A few hours after several reports suggested that AstraZeneca's side effects include blood clotting, the EU drug regulator has asked to add severe allergies to the list of side-effects from this<a href="https://www.wionews.com/topics/coronavirus-vaccine?page=1"> coronavirus vaccine.</a>

On Friday, the EU drug regulator said that severe allergies should be added to the possible side effects of AstraZeneca's coronavirus vaccine as the regulator has found likely links of such cases in the UK.

Also read |&nbsp;<a href="https://www.wionews.com/world/excellent-vaccine-who-backs-use-of-astrazenecas-coronavirus-vaccine-369954" hreflang="en">'Excellent vaccine': WHO backs use of AstraZeneca's coronavirus vaccine</a>

The EMA said it had "recommended an update to the product information to include anaphylaxis and hypersensitivity (allergic reactions) as side effects".

This call for action has come a day after the European Medicines Agency (EMA) started an investigation of the claim that blood clots were formed in a handful of cases in Denmark after the patient got vaccinated with AstraZeneca's coronavirus vaccine.

Also read |&nbsp;<a href="https://www.wionews.com/world/who-assessing-reports-on-risks-related-to-astrazeneca-covid-vaccine-369845">WHO assessing reports on risks related to AstraZeneca Covid vaccine</a>

In the highlights of the EMA committee assessing risks of medications, the EMA said, "the update is based on a review of 41 reports of possible anaphylaxis seen among around 5 million vaccinations in the United Kingdom."

It has also asserted that the declaration has been made after a review of the provided data. "After careful review of the data, (the committee) considered that a link to the vaccine was likely in at least some of these cases," it said.

Also read |&nbsp;<a href="https://www.wionews.com/world/oxford-astrazeneca-covid-19-vaccine-can-be-used-until-probe-results-eu-regulator-369788" hreflang="en">Oxford-AstraZeneca Covid-19 vaccine can be used until probe results: EU regulator</a>

This has also raised an important warning by AstraZeneca where the company has asked that the people receiving the jab should be kept under "close observation for at least 15 minutes" after getting inoculated, to monitor any allergic reactions.

Meanwhile, AstraZeneca has also issued a statement assuring that its coronavirus vaccine is safe to be used and has dismissed blood clotting as a side effect.

"An analysis of our safety data of more than 10 million records has shown no evidence of an increased risk of pulmonary embolism or deep vein thrombosis in any defined age group, gender, batch or in any particular country," a spokesperson said.

"In fact, the observed number of these types of events are significantly lower in those vaccinated than would be expected among the general population."

A few hours after several reports suggested that AstraZeneca's side effects include blood clotting, the EU drug regulator has asked to add severe allergies to the list of side-effects from this coronavirus vaccine.

A few hours after several reports suggested that AstraZeneca's side effects include blood clotting, the EU drug regulator has asked to add severe allergies to the list of side-effects from this coronavirus vaccine. On Friday, the EU drug regulator said that severe allergies should be added to the possible side effects of AstraZeneca's coronavirus vaccine as the regulator has found likely links of such cases in the UK. Also read | 'Excellent vaccine': WHO backs use of AstraZeneca's coronavirus vaccine The EMA said it had "recommended an update to the product information to include anaphylaxis and hypersensitivity (allergic reactions) as side effects". This call for action has come a day after the European Medicines Agency (EMA) started an investigation of the claim that blood clots were formed in a handful of cases in Denmark after the patient got vaccinated with AstraZeneca's coronavirus vaccine. Also read | WHO assessing reports on risks related to AstraZeneca Covid vaccine In the highlights of the EMA committee assessing risks of medications, the EMA said, "the update is based on a review of 41 reports of possible anaphylaxis seen among around 5 million vaccinations in the United Kingdom." It has also asserted that the declaration has been made after a review of the provided data. "After careful review of the data, (the committee) considered that a link to the vaccine was likely in at least some of these cases," it said. Also read | Oxford-AstraZeneca Covid-19 vaccine can be used until probe results: EU regulator This has also raised an important warning by AstraZeneca where the company has asked that the people receiving the jab should be kept under "close observation for at least 15 minutes" after getting inoculated, to monitor any allergic reactions. Meanwhile, AstraZeneca has also issued a statement assuring that its coronavirus vaccine is safe to be used and has dismissed blood clotting as a side effect. "An analysis of our safety data of more than 10 million records has shown no evidence of an increased risk of pulmonary embolism or deep vein thrombosis in any defined age group, gender, batch or in any particular country," a spokesperson said. "In fact, the observed number of these types of events are significantly lower in those vaccinated than would be expected among the general population."

Severe allergy side-effect of AstraZeneca coronavirus vaccine: EU drug regulator

After a flurry of concerning reports from various resources, the World Health Organization (WHO) has backed the use of AstraZeneca's <a href="https://www.wionews.com/topics/coronavirus-vaccine">coronavirus vaccine.</a>

"AstraZeneca is an excellent vaccine, as are the other vaccines that are being used," the WHO spokeswoman Margaret Harris said.

Also read |&nbsp;<a href="https://www.wionews.com/world/who-assessing-reports-on-risks-related-to-astrazeneca-covid-vaccine-369845">WHO assessing reports on risks related to AstraZeneca Covid vaccine</a>

WHO's Global Advisory Committee on Vaccine Safety (GACVS) has been assessing the reports on the concerns of risks of side-effects including blood clots.

The concern was raised by several European states who even suggested temporarily suspending the usage of AstraZeneca's coronavirus vaccine worrying about its possible side-effects on the locals.

However, a WHO spokesperson clarified saying there is no reason not to use the AstraZeneca vaccine. "Yes, we should continue using the AstraZeneca vaccine," Margaret Harris said. "There is no indication to not use it."

<a href="https://www.wionews.com/videos/european-medical-agencies-backs-astrazeneca-vaccine-after-suspensions-369937">WATCH |</a>

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/european-medical-agencies-backs-astrazeneca-vaccine-after-suspensions-369937/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

For now, the WHO has also clarified that although its advisory committee is currently studying the safety data provided, there is no causal link between the vaccine and blood clotting.

"We've reviewed the data on deaths. There has been no death, to date, proven to have be caused by vaccination," Harris claimed.

Meanwhile,&nbsp;Denmark, Norway, Iceland, Italy and Romania have limited and postponed the rollout of the AstraZeneca coronavirus vaccine since&nbsp;isolated reports of recipients developing blood clots.

While Harris has backed the AstraZeneca coronavirus vaccine on behalf of WHO, she has also stressed that any safety signal must be investigated.

"We must always ensure that we look for any safety signals when we roll out vaccines, and we must review them," she said. "But there is no indication to not use it."

After a flurry of concerning reports from various resources, the World Health Organization (WHO) has backed the use of AstraZeneca's coronavirus vaccine. "AstraZeneca is an excellent vaccine, as are the other vaccines that are being used," the WHO spokeswoman Margaret Harris said.

After a flurry of concerning reports from various resources, the World Health Organization (WHO) has backed the use of AstraZeneca's coronavirus vaccine. "AstraZeneca is an excellent vaccine, as are the other vaccines that are being used," the WHO spokeswoman Margaret Harris said. Also read | WHO assessing reports on risks related to AstraZeneca Covid vaccine WHO's Global Advisory Committee on Vaccine Safety (GACVS) has been assessing the reports on the concerns of risks of side-effects including blood clots. The concern was raised by several European states who even suggested temporarily suspending the usage of AstraZeneca's coronavirus vaccine worrying about its possible side-effects on the locals. However, a WHO spokesperson clarified saying there is no reason not to use the AstraZeneca vaccine. "Yes, we should continue using the AstraZeneca vaccine," Margaret Harris said. "There is no indication to not use it." WATCH | For now, the WHO has also clarified that although its advisory committee is currently studying the safety data provided, there is no causal link between the vaccine and blood clotting. "We've reviewed the data on deaths. There has been no death, to date, proven to have be caused by vaccination," Harris claimed. Meanwhile, Denmark, Norway, Iceland, Italy and Romania have limited and postponed the rollout of the AstraZeneca coronavirus vaccine since isolated reports of recipients developing blood clots. While Harris has backed the AstraZeneca coronavirus vaccine on behalf of WHO, she has also stressed that any safety signal must be investigated. "We must always ensure that we look for any safety signals when we roll out vaccines, and we must review them," she said. "But there is no indication to not use it."

'Excellent vaccine': WHO backs use of AstraZeneca's coronavirus vaccine

'There is currently no indication that the vaccination has caused these conditions, which are not listed as side effects with this vaccine', says European Medicines Agency

European Medical Agencies backs AstraZeneca vaccine after suspensions

Denmark, Norway and Iceland halt the COVID-19's vaccine AstraZeneca rollout after the recent blood clot reports. This vaccine will be suspended for 14 days in Denmark.

European Union nations halt AstraZeneca rollout over blood clot reports

After several Nordic nations suspended the use of Oxford-AstraZeneca's <a href="https://www.wionews.com/topics/coronavirus-vaccine">coronavirus vaccine</a>, the European Union's drug regulator advised European countries to keep using the jabs during a probe of blood clots cases.&nbsp;

"The position of EMA's safety committee... is that the vaccine's benefits continue to outweigh its risks and the vaccine can continue to be administered while investigation of cases of thromboembolic events is ongoing," European Medicines Agency (EMA) in a statement said.&nbsp;

Watch |&nbsp;

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/astrazeneca-vaccine-effective-against-brazil-variant-study-368333/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

"There is currently no indication that vaccination has caused these conditions, which are not listed as side effects with this vaccine."

The regulator's assurance comes after the United Kingdom defended Oxford's vaccine, saying it's "safe and effective".&nbsp;

"We've been clear that it's both safe and effective... and when people are asked to come forward and take it, they should do so in confidence," PM Boris Johnson's spokesman told reporters.

Also read | <a href="https://www.wionews.com/world/denmark-suspends-use-of-astrazeneca-covid-vaccine-due-to-blood-clot-fears-369692">Denmark, Norway suspend use of AstraZeneca COVID vaccine due to blood clot fears</a>

He also said that country's vaccine programme results have lowered the number of Covid-19 cases, hospitalisations, and deaths, suggesting that the vaccine is safe.&nbsp;

Denmark, Norway and Iceland on Thursday temporarily paused the use of AstraZeneca's vaccine over cases of patients developing blood clots after receiving jabs.

Amongst the three nations, Denmark was the first to announce the suspension, with the country's health authority saying "serious cases of blood clots" have been detected.

However, it said that the measure is "precautionary" and at the moment it has found no connection between AstraZeneca's jabs and blood clots.

After several Nordic nations suspended the use of Oxford-AstraZeneca's coronavirus vaccine, the European Union's drug regulator advised European countries to keep using the jabs during a probe of blood clots cases.

After several Nordic nations suspended the use of Oxford-AstraZeneca's coronavirus vaccine, the European Union's drug regulator advised European countries to keep using the jabs during a probe of blood clots cases. "The position of EMA's safety committee... is that the vaccine's benefits continue to outweigh its risks and the vaccine can continue to be administered while investigation of cases of thromboembolic events is ongoing," European Medicines Agency (EMA) in a statement said. Watch | "There is currently no indication that vaccination has caused these conditions, which are not listed as side effects with this vaccine." The regulator's assurance comes after the United Kingdom defended Oxford's vaccine, saying it's "safe and effective". "We've been clear that it's both safe and effective... and when people are asked to come forward and take it, they should do so in confidence," PM Boris Johnson's spokesman told reporters. Also read | Denmark, Norway suspend use of AstraZeneca COVID vaccine due to blood clot fears He also said that country's vaccine programme results have lowered the number of Covid-19 cases, hospitalisations, and deaths, suggesting that the vaccine is safe. Denmark, Norway and Iceland on Thursday temporarily paused the use of AstraZeneca's vaccine over cases of patients developing blood clots after receiving jabs. Amongst the three nations, Denmark was the first to announce the suspension, with the country's health authority saying "serious cases of blood clots" have been detected. However, it said that the measure is "precautionary" and at the moment it has found no connection between AstraZeneca's jabs and blood clots.

Oxford-AstraZeneca Covid-19 vaccine can be used until probe results: EU regulator

The European Union on Thursday&nbsp;approved Johnson &amp; Johnson's single-dose coronavirus vaccine, as the bloc seeks to speed up a stuttering inoculation campaign and boost its supplies of vaccines.

&nbsp;

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
📢 EMA has just recommended granting a conditional marketing authorisation for <a href="https://twitter.com/hashtag/COVID19vaccine?src=hash&amp;ref_src=twsrc%5Etfw">#COVID19vaccine</a> Janssen to prevent <a href="https://twitter.com/hashtag/COVID19?src=hash&amp;ref_src=twsrc%5Etfw">#COVID19</a> in people from 18 years of age. 
👉 <a href="https://t.co/j7jetH1Tbx">https://t.co/j7jetH1Tbx</a> <a href="https://t.co/cKGKujrqYp">pic.twitter.com/cKGKujrqYp</a>
— EU Medicines Agency (@EMA_News) <a href="https://twitter.com/EMA_News/status/1370002324605853701?ref_src=twsrc%5Etfw">March 11, 2021</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

Johnson&nbsp;&amp;&nbsp;Johnson is the fourth to be endorsed for use in the EU after Pfizer-BioNTech, AstraZeneca-Oxford University and Moderna. Three other vaccines are under "rolling review" by the Amsterdam-based EMA,&nbsp;Novavax, CureVac and Russia's Sputnik.&nbsp;

Also read|&nbsp;<a href="https://www.wionews.com/world/denmark-suspends-use-of-astrazeneca-covid-vaccine-due-to-blood-clot-fears-369692" hreflang="en">Denmark suspends use of AstraZeneca COVID vaccine due to blood clot fears&nbsp;</a>

US pharma giant J&amp;J filed on February 16 for approval for the vaccine, developed by its Belgian subsidiary Janssen.&nbsp;The company has committed to deliver 200 million doses of its vaccine to the bloc this year.

As well as being the first that requires a single injection as opposed to two, the Johnson &amp; Johnson vaccine is easier to store.

The J&amp;J shot however appears less protective than Pfizer and Moderna's regimes, which both have an efficacy of around 95 per cent against all forms of Covid-19 from the classic coronavirus strain.

'Bumpy' strategy'

The EU has been struggling with a disappointing vaccination rollout that started in January and faltered because of a lack of doses produced by the three suppliers so far.&nbsp;

The head of the EU's vaccine supply task force, Thierry Breton, said on Tuesday the EU's "bumpy" vaccine strategy should be augmented by the addition of the Johnson &amp; Johnson jab.

Reported production shortfalls in the United States by Johnson &amp; Johnson would not impact the EU because Brussels had made contingency plans for all vaccines, he said.

"Do not believe that because one company has a problem that overall it will jeopardise the whole programme," said Breton, the EU's industry commissioner.

Europe's vaccination strategy faced fresh problems on Wednesday as Denmark and Norway said they were temporarily suspending the use of AstraZeneca's Covid-19 vaccine after some patients developed blood clots

The European Union on Thursday approved Johnson & Johnson's single-dose coronavirus vaccine, as the bloc seeks to speed up a stuttering inoculation campaign and boost its supplies of vaccines.

The European Union on Thursday approved Johnson & Johnson's single-dose coronavirus vaccine, as the bloc seeks to speed up a stuttering inoculation campaign and boost its supplies of vaccines. 📢 EMA has just recommended granting a conditional marketing authorisation for #COVID19vaccine Janssen to prevent #COVID19 in people from 18 years of age. 👉 https://t.co/j7jetH1Tbx pic.twitter.com/cKGKujrqYp — EU Medicines Agency (@EMA_News) March 11, 2021 × Johnson & Johnson is the fourth to be endorsed for use in the EU after Pfizer-BioNTech, AstraZeneca-Oxford University and Moderna. Three other vaccines are under "rolling review" by the Amsterdam-based EMA, Novavax, CureVac and Russia's Sputnik. Also read| Denmark suspends use of AstraZeneca COVID vaccine due to blood clot fears US pharma giant J&J filed on February 16 for approval for the vaccine, developed by its Belgian subsidiary Janssen. The company has committed to deliver 200 million doses of its vaccine to the bloc this year. As well as being the first that requires a single injection as opposed to two, the Johnson & Johnson vaccine is easier to store. The J&J shot however appears less protective than Pfizer and Moderna's regimes, which both have an efficacy of around 95 per cent against all forms of Covid-19 from the classic coronavirus strain. 'Bumpy' strategy' The EU has been struggling with a disappointing vaccination rollout that started in January and faltered because of a lack of doses produced by the three suppliers so far. The head of the EU's vaccine supply task force, Thierry Breton, said on Tuesday the EU's "bumpy" vaccine strategy should be augmented by the addition of the Johnson & Johnson jab. Reported production shortfalls in the United States by Johnson & Johnson would not impact the EU because Brussels had made contingency plans for all vaccines, he said. "Do not believe that because one company has a problem that overall it will jeopardise the whole programme," said Breton, the EU's industry commissioner. Europe's vaccination strategy faced fresh problems on Wednesday as Denmark and Norway said they were temporarily suspending the use of AstraZeneca's Covid-19 vaccine after some patients developed blood clots

European Union gives green light to Johnson & Johnson's COVID-19 vaccine

Health authorities in Denmark said on Thursday said that they were temporarily suspending use of COVID-19 vaccine. This precaution is being taken as some patients developed blood clots after they received the vaccine.&nbsp;

Danish Health Authority said in statement that suspension of AstraZeneca vaccine came "following reports of serious cases of blood clots among people vaccinated with AstraZeneca's Covid-19 vaccine"

However, it added that "it has not been determined, at the time being, that there is a link between the vaccine and the blood clots"

Hours after Denmark's decision, Norwegian health authorities said that they were suspending the use of AstraZeneca vaccine as a precaution.

"We are pausing the AstraZeneca vaccination in Norway," the director of infection prevention and control at the National Institute of Health, Geir Bukholm, told reporters.&nbsp;

"We are waiting for more information to see if there is a link between the vaccine and this blood clot case," he said.

Austria announced on Monday that it had suspended the use of a batch of AstraZeneca vaccines after a 49-year-old nurse died of "severe blood coagulation problems" days after receiving an anti-Covid shot.

Four other European countries -- Estonia, Latvia, Lithuania and Luxemburg -- have also suspended the use of vaccines from this batch, which was sent to 17 European countries and consisting of one million jabs.

Denmark has however suspended the use of all of its AstraZeneca supply.

On Wednesday, &nbsp;Europe's medicines watchdog EMA said a preliminary probe showed that the batch of AstraZeneca vaccines used in Austria was likely not to blame for the nurse's death.

As of March 9, 22 cases of blood clots had been reported among more than three million people vaccinated in the European Economic Area, the EMA said.

Meanwhile UK PM Boris Johnson's spokesperson said on Thursday that AstraZeneca vaccine was safe.

"We've been clear that it's both safe and effective... and when people are asked to come forward and take it, they should do so in confidence," said the official spokesperson

(With AFP inputs)

Health authorities in Denmark said on Thursday said that they were temporarily suspending use of COVID-19 vaccine. This precaution is being taken as some patients developed blood clots after they received the vaccine.

Health authorities in Denmark said on Thursday said that they were temporarily suspending use of COVID-19 vaccine. This precaution is being taken as some patients developed blood clots after they received the vaccine. Danish Health Authority said in statement that suspension of AstraZeneca vaccine came "following reports of serious cases of blood clots among people vaccinated with AstraZeneca's Covid-19 vaccine" However, it added that "it has not been determined, at the time being, that there is a link between the vaccine and the blood clots" Hours after Denmark's decision, Norwegian health authorities said that they were suspending the use of AstraZeneca vaccine as a precaution. "We are pausing the AstraZeneca vaccination in Norway," the director of infection prevention and control at the National Institute of Health, Geir Bukholm, told reporters. "We are waiting for more information to see if there is a link between the vaccine and this blood clot case," he said. Austria announced on Monday that it had suspended the use of a batch of AstraZeneca vaccines after a 49-year-old nurse died of "severe blood coagulation problems" days after receiving an anti-Covid shot. Four other European countries -- Estonia, Latvia, Lithuania and Luxemburg -- have also suspended the use of vaccines from this batch, which was sent to 17 European countries and consisting of one million jabs. Denmark has however suspended the use of all of its AstraZeneca supply. On Wednesday, Europe's medicines watchdog EMA said a preliminary probe showed that the batch of AstraZeneca vaccines used in Austria was likely not to blame for the nurse's death. As of March 9, 22 cases of blood clots had been reported among more than three million people vaccinated in the European Economic Area, the EMA said. Meanwhile UK PM Boris Johnson's spokesperson said on Thursday that AstraZeneca vaccine was safe. "We've been clear that it's both safe and effective... and when people are asked to come forward and take it, they should do so in confidence," said the official spokesperson (With AFP inputs)

Denmark, Norway suspend use of AstraZeneca COVID vaccine due to blood clot fears 

Kremlin on Tuesday slammed&nbsp;claims it was spearheading a disinformation campaign against US-made coronavirus vaccines to boost its own homegrown jab were "absurd and groundless".&nbsp;

The comments come a day after Washington said Russian intelligence was behind four websites involved in a campaign to undermine US-made vaccines, accusing Russia of putting lives at risk.&nbsp;

Also read:&nbsp;<a href="https://www.wionews.com/world/russia-risking-lives-by-running-disinformation-campaign-against-vaccines-us-369006">Russia risking lives by running disinformation campaign against vaccines: US</a>

Russian President Vladimir Putin's spokesman Dmitry Peskov called the allegations "absurd and groundless".

"Russia has never taken part and is not going to take part in such information campaigns against other vaccines," Peskov told reporters.

On the contrary, he said, Russia was cooperating with foreign vaccine producers "to make a more effective product".

"We've always been against politicising any issues related to the vaccine in any way," he said.

Peskov added that once jabs are tested and approved "they should be produced as much as possible to save the entire world from the coronavirus and save as many human lives as possible".

Putin has boasted that Russia has developed the world's best vaccines against the coronavirus, insisting last week they were better than the Pfizer and AstraZeneca jabs.

The Global Engagement Center -- an arm of the State Department whose activities include monitoring foreign propaganda -- made the claims of Russian disinformation on Monday.&nbsp;

The four online platforms spread "disinformation about two of the vaccines that have now been approved by the FDA in this country," US State Department spokesman Ned Price told reporters, referring to the US Food and Drug Administration.

US intelligence has long suspected Russia in disinformation campaigns on health, including spreading the myth in the 1980s that US scientists created the HIV virus that causes AIDS.

Kremlin on Tuesday slammed claims it was spearheading a disinformation campaign against US-made coronavirus vaccines to boost its own homegrown jab were "absurd and groundless".

Kremlin on Tuesday slammed claims it was spearheading a disinformation campaign against US-made coronavirus vaccines to boost its own homegrown jab were "absurd and groundless". The comments come a day after Washington said Russian intelligence was behind four websites involved in a campaign to undermine US-made vaccines, accusing Russia of putting lives at risk. Also read: Russia risking lives by running disinformation campaign against vaccines: US Russian President Vladimir Putin's spokesman Dmitry Peskov called the allegations "absurd and groundless". "Russia has never taken part and is not going to take part in such information campaigns against other vaccines," Peskov told reporters. On the contrary, he said, Russia was cooperating with foreign vaccine producers "to make a more effective product". "We've always been against politicising any issues related to the vaccine in any way," he said. Peskov added that once jabs are tested and approved "they should be produced as much as possible to save the entire world from the coronavirus and save as many human lives as possible". Putin has boasted that Russia has developed the world's best vaccines against the coronavirus, insisting last week they were better than the Pfizer and AstraZeneca jabs. The Global Engagement Center -- an arm of the State Department whose activities include monitoring foreign propaganda -- made the claims of Russian disinformation on Monday. The four online platforms spread "disinformation about two of the vaccines that have now been approved by the FDA in this country," US State Department spokesman Ned Price told reporters, referring to the US Food and Drug Administration. US intelligence has long suspected Russia in disinformation campaigns on health, including spreading the myth in the 1980s that US scientists created the HIV virus that causes AIDS.

Kremlin slams US vaccine disinformation claims 'absurd' and 'groundless'

Days after India gifted vaccines to Mongolia, the country is keen to get more vaccines from New Delhi, this time commercially.&nbsp;

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
Caring for a Spiritual Neighbour. Made in India vaccines reach Mongolia. <a href="https://twitter.com/hashtag/VaccineMaitri?src=hash&amp;ref_src=twsrc%5Etfw">#VaccineMaitri</a> <a href="https://t.co/8wIRImXX7D">pic.twitter.com/8wIRImXX7D</a>
— Dr. S. Jaishankar (@DrSJaishankar) <a href="https://twitter.com/DrSJaishankar/status/1363712034337034241?ref_src=twsrc%5Etfw">February 22, 2021</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

The deputy Prime Minister of Mongolia has written to India's external affairs minister Dr. S Jaishankar requesting for 10 to 15 lakh India-made vaccines Covishield.

India had gifted 1.5 lakh doses of Covishield vaccine to Mongolia on February 21 that helped the country begin its vaccination drive.&nbsp;

Interestingly, the Prime Minister of Mongolia Luvsannamsrain Oyun-Erdene was vaccinated using India-made vaccines. What makes Covishield is the AstraZeneca-Oxford vaccine produced by Pune-based Serum Institute of India much sought after is that it has got approval from the World Health Organization (WHO).

India and Mongolia share close ties and have seen a number of visits including the famous visit of Indian PM Modi in 2015. Mongolia, landlocked between China and Russia considers India as its spiritual and third neighbour.

New Delhi's outreach on COVID-19 vaccines has been much appreciated globally with India sending 568.06 lakh doses of vaccines to 56 countries and UN Health workers.&nbsp;

Not only Mongolia but countries in South Asia - Afghanistan, Maldives, Nepal, Bangladesh and countries in Africa and Caricom region began their COVID-19 vaccination using India-made coronavirus vaccines.

Days after India gifted vaccines to Mongolia, the country is keen to get more vaccines from New Delhi, this time commercially. Caring for a Spiritual Neighbour. Made in India vaccines reach Mongolia.

Days after India gifted vaccines to Mongolia, the country is keen to get more vaccines from New Delhi, this time commercially. Caring for a Spiritual Neighbour. Made in India vaccines reach Mongolia. #VaccineMaitri pic.twitter.com/8wIRImXX7D — Dr. S. Jaishankar (@DrSJaishankar) February 22, 2021 × The deputy Prime Minister of Mongolia has written to India's external affairs minister Dr. S Jaishankar requesting for 10 to 15 lakh India-made vaccines Covishield. India had gifted 1.5 lakh doses of Covishield vaccine to Mongolia on February 21 that helped the country begin its vaccination drive. Interestingly, the Prime Minister of Mongolia Luvsannamsrain Oyun-Erdene was vaccinated using India-made vaccines. What makes Covishield is the AstraZeneca-Oxford vaccine produced by Pune-based Serum Institute of India much sought after is that it has got approval from the World Health Organization (WHO). India and Mongolia share close ties and have seen a number of visits including the famous visit of Indian PM Modi in 2015. Mongolia, landlocked between China and Russia considers India as its spiritual and third neighbour. New Delhi's outreach on COVID-19 vaccines has been much appreciated globally with India sending 568.06 lakh doses of vaccines to 56 countries and UN Health workers. Not only Mongolia but countries in South Asia - Afghanistan, Maldives, Nepal, Bangladesh and countries in Africa and Caricom region began their COVID-19 vaccination using India-made coronavirus vaccines.

Mongolia requests for more vaccines from India

The European Union has come out in support of Italy's decision to block the supply of the AstraZeneca Vaccine to Australia on Saturday. The EU internal market commissioner said that the block has to make sure that the company deliver what it expects.

Italy bans the supply of the AstraZeneca Vaccine to Australia

The European Union is planning to ask the United States to permit the export of millions of doses of AstraZeneca's Covid vaccine.

According to a report published in the Financial Times, the 27-nation EU also wants Washington to ensure the free flow of shipments of crucial vaccine ingredients needed in European production.

The FT quoted the European Commission as saying in Saturday: "We trust that we can work together with the US to ensure that vaccines produced or bottled in the US for the fulfilment of vaccine producers' contractual obligations with the EU will be fully honoured."

The EU countries started inoculations at the end of December, but are moving at a far slower pace than other rich nations, including former member Britain and the United States. Officials have so far blamed the slow progress in part on supply problems with manufacturers.

The European Commission and Italy this week blocked a shipment of AstraZeneca's coronavirus vaccine destined for Australia after the drug manufacturer failed to meet its EU contract commitments.&nbsp;

The Anglo-Swedish drugmaker has been under fire in the EU for its delayed supplies of shots to the 27-nation bloc, which ordered 300 million doses by the end of June.&nbsp;

AstraZeneca's CEO Pascal Soriot told EU lawmakers in a public hearing in February that they were working to improve the delivery and resolve issues.

(with inputs)

The European Union is planning to ask the United States to permit the export of millions of doses of AstraZeneca's Covid vaccine. According to a report published in the Financial Times, the 27-nation EU also wants Washington to ensure the free flow of shipments of crucial vaccine ingredients needed in European production.

The European Union is planning to ask the United States to permit the export of millions of doses of AstraZeneca's Covid vaccine. According to a report published in the Financial Times, the 27-nation EU also wants Washington to ensure the free flow of shipments of crucial vaccine ingredients needed in European production. The FT quoted the European Commission as saying in Saturday: "We trust that we can work together with the US to ensure that vaccines produced or bottled in the US for the fulfilment of vaccine producers' contractual obligations with the EU will be fully honoured." The EU countries started inoculations at the end of December, but are moving at a far slower pace than other rich nations, including former member Britain and the United States. Officials have so far blamed the slow progress in part on supply problems with manufacturers. The European Commission and Italy this week blocked a shipment of AstraZeneca's coronavirus vaccine destined for Australia after the drug manufacturer failed to meet its EU contract commitments. The Anglo-Swedish drugmaker has been under fire in the EU for its delayed supplies of shots to the 27-nation bloc, which ordered 300 million doses by the end of June. AstraZeneca's CEO Pascal Soriot told EU lawmakers in a public hearing in February that they were working to improve the delivery and resolve issues. (with inputs)

EU wants access to US produced AstraZeneca vaccines, report says

Preliminary data from a study conducted at the University of Oxford indicates that the Covid-19 vaccine developed by AstraZeneca PLC is effective against the P1

AstraZeneca vaccine effective against Brazil variant: Study

A new study suggests that the Oxford-AstraZeneca vaccine is effective even in the elderly population. According to the research, the Oxford-AstraZeneca vaccine appears to be more than 80 per cent effective.

Study suggests Oxford-AstraZeneca vaccine effective in over-80s

astrazeneca

Astrazeneca, News on Astrazeneca, stories on Astrazeneca, articles on Astrazeneca, Astrazeneca stories at Wion, Astrazeneca news, Astrazeneca latest news